MAYO CLINIC
Q1 2020 Form 13-F

ROCHESTER, MINNESOTA
CIK 0001318153 · Institutional investment manager
$39.5M Reported Value Total
Reported value
$39.5M
Quarter over quarter
-55.3%
Holdings
7
Top-10 concentration
100.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Paul A Gorman
Chief Investment Officer
Q4 2019
Q2 2020
Go to latest
Loading 13F Metrics

Q1 2020 13F filing summary

Period of report March 31, 2020
Filed April 24, 2020
Form 13F-HR
Reported value $39.5M
Positions 7
Change in reported value -55.2%
New positions 1
Exited positions 2
Position turnover 33.3%
Top-10 concentration 100.0%

13F filings by quarter

Quarter Positions Value
Q3 2024 13F
Filed Nov 12, 2024
 3 $2.9M
Q2 2024 13F
Filed Aug 12, 2024
 4 $3.0M
Q1 2024 13F
Filed May 13, 2024
 5 $6.1M
Q4 2023 13F
Filed Feb 13, 2024
 7 $16.2M
Q3 2023 13F
Filed Nov 14, 2023
 9 $51.9M
Q2 2023 13F
Filed Aug 9, 2023
 11 $97.4M
Q1 2023 13F
Filed May 5, 2023
 13 $121.8M
Q4 2022 13F
Filed Jan 26, 2023
 13 $188.8M
Q2 2021 13F
Filed Aug 12, 2021
 9 $90.4M
Q1 2021 13F
Filed May 13, 2021
 8 $86.9M
Q4 2020 13F
Filed Feb 11, 2021
 9 $83.1M
Q3 2020 13F
Filed Nov 12, 2020
 9 $74.2M
Q2 2020 13F
Filed Aug 13, 2020
 8 $104.5M
Q1 2020 13F
Filed Apr 24, 2020
 7 $39.5M
Q4 2019 13F
Filed Feb 12, 2020
 8 $88.2M

Top 7 holdings · Q1 2020

# Holding Reported value % of portfolio
1 BSM Black Stone Minerals $26.7M 67.58%
2 UBX Unity Biotechnology Inc $9.1M 23.05%
3 EVLO Evelo Bioseciences Inc $1.8M 4.61%
4 BSGM Biosig Tech Inc $849.0K 2.15%
5 MCRB Seres Therapeutics Inc $643.0K 1.63%
6 EXAS Exact Sciences Corp $220.0K 0.56%
7 CLPT Clearpoint Neuro Inc (fka MRI Interventions Inc) $169.0K 0.43%

Values as reported on the Q1 2020 Form 13F. Every position is in the holdings table below.

Loading Activities
Loading Sector Allocation
Crunching numbers
Loading Performance
Finding Potential New Buys
Building table
Loading SEC filing data
Loading Form 4 Filings
Loading 13D/G filings